Silk Road Medical to Present at the BofA Securities 2022 Healthcare Conference
Silk Road Medical (Nasdaq: SILK), dedicated to decreasing stroke risk, will participate in the BofA Securities 2022 Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Silk Road Medical (Nasdaq: SILK), dedicated to decreasing stroke risk, will participate in the BofA Securities 2022 Healthcare Conference. The presentation is scheduled for May 11, 2022, at 5:20 p.m. PT. Interested individuals can access the live and archived webcast through the company's investors' section. The company is recognized for its innovative TransCarotid Artery Revascularization (TCAR) procedure, which aims to treat carotid artery disease and enhance patient outcomes.
Details
News Market Reaction – SILK
The recorded move for SILK in the trading session of this news was -4.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming BofA Securities 2022 Healthcare Conference.
Management is scheduled to present on Wednesday, May 11, 2022 at 5:20 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.silkroadmed.com/.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.
Investor Contact:
Lynn Lewis or Marissa Bych
Gilmartin Group
investors@silkroadmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.